Skip to main content
SpringerLink
Log in

Commentary on Section III

  • Chapter
Book cover Immunology for Surgeons

  • 142 Accesses

Abstract

In Chapter 10, Killion and Fidler discuss the immunobiology of the metastatic process and the nature of the host response in cancer dissemination. Recently, there has been great emphasis on the detection of low burden circulating and sequestered (mostly bone marrow) tumor cells in solid epithelial malignancies such as gastric, colonic, breast and lung carcinoma [1–3]. This finding will probably define the need for systemic therapy when conventional staging suggests that disease is localized and it may also act as a new surrogate end-point for the determination of adjuvant responses.

The aim of this review section is to highlight important areas covered in the chapters concerning tumor immunology and to introduce potential future immunotherapeutic strategies in specific malignancies raised in these chapters.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cote RJ, Beattie EJ, Chaiwun B, Shi SR, Harvey J, Chen SC, et al. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma. Ann Surg 1995;222:415–25.

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Calaluce R, Miedema BW, Yesus YW. Micrometastases in colorectal carcinoma: a review. J Surg Oncol 1998;67:194–202.

    CAS  PubMed  Google Scholar 

  3. Muller P, Schlimok G. Bone marrow “micrometastases” of epithelial tumors: detection and clinical relevance. J Cancer Res Clin Oncol 2000;126:607–18.

    CAS  PubMed  Google Scholar 

  4. Zhong XY, Kaul S, Lin YS, Eichler A, Bastert G. Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin-19. J Cancer Res Clin Oncol 2000;126:212–8.

    CAS  PubMed  Google Scholar 

  5. Zippelius A, Kufer P, Honold G, Kollermann MW, Oberneder R, Schlimok G, et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997;15:2701–8.

    CAS  PubMed  Google Scholar 

  6. Fox SB, Leek RD, Bliss J, Mansi JL, Gusterson B, Gatter KC, et al. Association of tumor angiogenesis with bone marrow micro metastases in breast cancer patients. J Natl Cancer Inst 1997;89:1044–9.

    CAS  PubMed  Google Scholar 

  7. Murphy J, O’Sullivan GC, Lee G, Madden M, Shanahan F, Collins JK, et al. The inflammatory response within Dukes’ B colorectal cancer: implications for progression of micrometastases and patient survival. Am J Gastroenterol 2000;95:3607–14.

    CAS  PubMed  Google Scholar 

  8. Hilburger Ryan M, Abrams SI. Characterization of CD8+ cytotoxic lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 2001;49:603–12.

    Google Scholar 

  9. Seymour K, Pettit S, O’Flaherty E, Charnley RM, Kirby JA. Selection of metastatic tumor phenotypes by host immune systems. Lancet 1999;354(9194):1989–91.

    CAS  PubMed  Google Scholar 

  10. Yoo NC, Chung HC, Chung HC, Park JO, Rha SY, Kim JH, et al. Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-I) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression. Yonsei Med J 1998;39:27–36.

    CAS  PubMed  Google Scholar 

  11. Velikova G, Banks RE, Gearing A, Hemingway I, Forbes MA, Preston SR, et al. Serum concentrations of soluble adhesion molecules in patients with colorectal cancer. Br J Cancer 1998;77:1857–63.

    CAS  PubMed Central  PubMed  Google Scholar 

  12. Sanchez-Rovira P, Jimenez E, Carracedo J, Barneto IC, Ramirez R, Aranda E. Serum levels of intercellular adhesion molecule 1 (ICAM-1) in patients with colorectal cancer: inhibitory effect on cytotoxicity. Eur J Cancer 1998;34:394–8.

    CAS  PubMed  Google Scholar 

  13. Koyama S. Immunosuppressive effect of shedding ICAM-1 antigen on cell-mediated cytotoxicity against tumor cells. Jpn J Cancer Res 1994;85:131–4.

    CAS  PubMed  Google Scholar 

  14. Becker JC, Termeer C, Schmidt RE, Brocker E-B. Soluble intercellular adhesion molecule 1 inhibits MHC-restricted specific T cell/tumor interaction. J Immunol 1993;151:7224–32.

    CAS  PubMed  Google Scholar 

  15. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst., 1990;82:4–6.

    CAS  PubMed  Google Scholar 

  16. Salven P, Mäenpää H, Orpana A, Alitalo K, Joensuu H. Serum vascular endothelial growth factor is often elevated in disseminated cancer. Clin Cancer Res 1997;3:647–51.

    CAS  PubMed  Google Scholar 

  17. Kumar H, Heer K, Lee PWR, Duthie GS, MacDonald AW, Greenman J, et al. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279–85.

    CAS  PubMed  Google Scholar 

  18. Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, et al. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 2000;7:333–8.

    CAS  PubMed  Google Scholar 

  19. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096–103.

    CAS  PubMed  Google Scholar 

  20. Lechner P, Lind P, Goldberg DM. Can postoperative surveillance with serial CEA immunoscintigraphy detect respectable cancer recurrence and potentially improve tumor-free survival? J Am Coli Surg 2000;191:511–8.

    CAS  Google Scholar 

  21. Lunniss PJ, Skinner S, Britton KE, Granowska M, Morris G, Northover JM. Effect of radioimmunoscintigraphy on the management of recurrent colorectal cancer. Br J Surg 1999;86:244–9.

    CAS  PubMed  Google Scholar 

  22. Szalai G, Williams LE, Primus FJ. Tumor targeting with radiolabeled antibodies in a human carcinoembryonic antigen transgenic mouse model. Int J Cancer 2000;85:751–6.

    CAS  PubMed  Google Scholar 

  23. Magnani P, Fazio F, Grana C, Songini C, Frigerio L, Pecorelli S, et al. Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy. Br J Cancer 2000;82:616–20.

    CAS  PubMed Central  PubMed  Google Scholar 

  24. Wilkomm P, Bender H, Bangard M, Decker P, Grunwald F, Biersack HJ. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma. J Nucl Med 2000;41:1657–63.

    Google Scholar 

  25. Buchsbaum DJ. Experimental radioimmunotherapy. Semin Radiat Oncol 2000;10:156–67.

    CAS  PubMed  Google Scholar 

  26. Jain RK. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Met Rev 1990;9:253–66.

    CAS  Google Scholar 

  27. Siavin-Chioriniu DC, Kashmiri SV, Lee HS, Milenic DE, Poole DJ, Bernon E, et al. A CDR-grafterd (humanized) domain-deleted antitumor antibody. Cancer Biother Radiopharm 1997;12:305–16.

    Google Scholar 

  28. Jurcic JG, Cathcart K, Pinilla-Ibarz J, Scheinberg DA. Advances in immunotherapy of hematologic malignancies:cellular and humoral approaches. Curr Opin Hematol 2000;7:247–54.

    CAS  PubMed  Google Scholar 

  29. Zbar AP, O’Higgins NJ. The use and abuse of TSH suppression therapy for benign and malignant thyroid neoplasms. In Surgery of the Thyroid and Parathyroid. OH Clark, Q-Y Duh, A Siperstein eds. WB Saunders San Francisco 1997;54–68.

    Google Scholar 

  30. Schmutzler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol 2000;143:15–24.

    CAS  PubMed  Google Scholar 

  31. Roselli M, Buonomo O, Piazza A, Guadagni F, Vecchione A, Brunetti E, Cipriani C, Amadei G, Nieroda C, Greiner JW, Casciani CU. Novel clinical approaches in monoclonal antibody-based management in colorectal cancer patients: radioimmunoguided surgery and antigen augmentation. Semin Surg Oncol 1998;15:254–62.

    CAS  PubMed  Google Scholar 

  32. Martinez DA, Barbera-Guillem E, La Valle GJ, Martin EW Jr. Radioimmunoguided surgery for gastrointestinal malignancies: an analysis of 14 years of clinical experience. Cancer Control 1997;4:505–16.

    PubMed  Google Scholar 

  33. Avital S, Haddad R, Troitsa A, Kashtan H, Brazovsky E, Gitstein G, et al. Radioimmunoguided surgery for recurrent colorectal cancer manifested by isolated CEA elevation. Cancer 2000;89:169–28.

    Google Scholar 

  34. Martin EW Jr, Thurston MO. Intraoperative radioimmunodetection. Semin Surg Oncol 1998;15:205–8.

    PubMed  Google Scholar 

  35. Nag S, Martinez-Monge R, Nieroda C, Martin E Jr. Radioimmunoguided-intraoperative radiation therapy in colorectal carcinoma: a new technique to precisely define the clinical target volume. Int J Radiat Oncol Biol Phys 1999;44:133–7.

    CAS  PubMed  Google Scholar 

  36. Schneebaum S, Even-Sapir E, Cohen M, Shacham-Lehrman H, Gat A, Brazovsky E, et al. Clinical applications of gamma-detection probes — radioguided surgery. Eur J Nucl Med 1999;26 (4 Suppl):S26–35.

    CAS  PubMed  Google Scholar 

  37. Merrie AEH, van Rij AM, Phillips LV, Rossaak JI, Yun K, McCall JL. Diagnostic use of the sentinel node in colon cancer. Diseases Colon Rectum 2001;44:410–7.

    CAS  Google Scholar 

  38. Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, Nebendahl K, et al. Therapeutic advantages of Auger electron-over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies. Eur J Nucl Med 2000;27:753–65.

    CAS  PubMed  Google Scholar 

  39. Reichert TE, Rabinowich H, Johnson JT et al. Immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 1998,21:295–308.

    CAS  PubMed  Google Scholar 

  40. Choi SH, Chung EJ, Whang DY et al. Alteration of signal-transducing molecules in tumor-infiltrating lymphocytes and peripheral blood T lymphocytes from human colorectal carcinoma patients. Cancer Immunol Immunopathol 1998,45:299–305.

    CAS  Google Scholar 

  41. Uzzo RG, Rayman P, Kolenko V et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999,5:1219–29.

    CAS  PubMed  Google Scholar 

  42. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the zeta chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998;58:5344–7.

    CAS  PubMed  Google Scholar 

  43. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL. Mechanisms responsible for signalling and functional defects. J Immunother 1998;21:295–306.

    CAS  PubMed  Google Scholar 

  44. Menne C, Lauritsen JP, Dietrich J, Kastrup J, Wegener AK, Andersen PS, et al. T-cell receptor downregulation by ceramide-induced caspase activation and cleavage of the zeta chain. Scand J Immunol 2001;53:176–83.

    CAS  PubMed  Google Scholar 

  45. Scaffidi C, Fulda S, Srinivasan A et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998, 17:1675–87.

    CAS  PubMed Central  PubMed  Google Scholar 

  46. Whiteside TL. Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signalling defects. Adv Exp Med Biol 1998;451:167–71.

    CAS  PubMed  Google Scholar 

  47. Bukowski RM, Rayman P, Uzzo R, Bloom T, Sabdstrom K, Peereboom D, et al. Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. Clin Cancer Res 1998;4:2337–47.

    CAS  PubMed  Google Scholar 

  48. Gratama JW, Zea AH, Bolhuis RL, Ochoa AC. Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer Immunol Immunother 1999;48:263–9.

    CAS  PubMed  Google Scholar 

  49. Uzzo RG, Rayman P, Kolenko V, Clark PE, Bloom T, Ward AM, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5:1219–29.

    CAS  PubMed  Google Scholar 

  50. Kolenko VM, Uzzo RG, Buzowski R, Finke JH. Caspase-dependent and — independent death pathways in cancer therapy. Apoptosis 2000;5:17–20.

    CAS  PubMed  Google Scholar 

  51. McGuiness RP, Ge Y, Patel SD, Kashmiri SV, Lee HS, Hand PH, et al. Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor. Hum Gene Ther 1999;20:165–73.

    Google Scholar 

  52. Abken H, Hombach A, Heuser C, Reinhold U. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. Rec Results Cancer Res 2001;158:249–64.

    CAS  Google Scholar 

  53. Durrant LG, Buckley TID, Denton GWL, Hardcastle JD, Sewell HF, Robins RA. Enhanced cellmediated tumor cell killing in patients immunized with human monoclonal anti-idiotypic antibody 105AD7. Cancer Res 1994;54:4837–80.

    CAS  PubMed  Google Scholar 

  54. Foon KA, John WI, Chakraborty M, Sherratt A, Garrison J, Flett M, et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics carcinoembryonic antigen. Clin Cancer Res 1998;3:1267–76.

    Google Scholar 

  55. Pervin S, Chakraborty M, Bhattacharya-Chatterjee M, Zeytin H, Foon KA, Chatterjee SK. Induction of anti-tumor immunity by an anti-idiotype antibody mimicking CEA. Am Assoc Cancer Res 1996;37:473–4(A # 3231).

    Google Scholar 

  56. Zbar AP, Snary D, Thomas H, Kmiot WA, Allen-Mersh TG. Immunoresponsiveness in metastatic colorectal cancer during anticarcinoembryonic antigen vaccination. Br J Surg 2000;87:627(A).

    Google Scholar 

  57. Zbar AP, Lemoine NR, Wadhwa M, Thomas H, Snary D, Kmiot WA. Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target. Br J Cancer 1998;77:683–93.

    CAS  PubMed Central  PubMed  Google Scholar 

  58. Foon KA. Immunotherapy for colorectal cancer. Curr Oncol Rep 2001;3:116–26.

    CAS  PubMed  Google Scholar 

  59. Syrigos KN, Karayiannakis AJ, Zbar A. Mucins as immunogenic targets in cancer. Anticancer Res 1999;19:5239–44.

    CAS  PubMed  Google Scholar 

  60. Conry RM, Allen KO, Lee S, Moore SE, Shaw DR, LoBugiio AF. Human autoantibodies to carcino embryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin Cancer Res 2000;6:34–41.

    CAS  PubMed  Google Scholar 

  61. Tsang KY, Zaremba S, Nieroda CA, Zhu MZ, Hamilton JM, Schlom J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst 1995;87:982–90.

    CAS  PubMed  Google Scholar 

  62. Conry RM, Widera G, LoBuglio AF, Fuller JT, Moore SE, Barlow DL, et al. Selected strategies to augment polynucleotide vaccination. Gene Ther 1996;3:67–74.

    CAS  PubMed  Google Scholar 

  63. Maruyama H, Zaloudik J, Li W, Sperlagh M, Koido T, Somasundaram R, et al. Cancer vaccines: single-epitope anti-idiotype vaccine versus multiple-epitope antigen vaccine. Cancer Immunol Immunother 2000;49:123–32.

    CAS  PubMed  Google Scholar 

  64. Vermorken JB, Claessen AM, van Tinteren H, Gall HE, Ezinga R, Meijer S, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomized trial. Lancet 1999;353(9150):345–50.

    CAS  PubMed  Google Scholar 

  65. Hanna MG, Hoover HC, Vermorken JB, Harris JE, Pinedo HM. Adjuvant active specific immunotherapy of stage II and stage III colon cancer with autologous tumor cell vaccine: first randomized phase III trials show promise. Vaccine 2001;19(17–19):2576–82.

    PubMed  Google Scholar 

  66. Chen W, Rains N, Young D, Stubbs RS. Dendritic cell-based cancer immunotherapy: potential for treatment of colorectal cancer? J Gastroenterol Hepatol 2000;15:698–705.

    CAS  PubMed  Google Scholar 

  67. Berger CL, Xu AL, Hanlon D, Lee C, Schechner J, Glusac E, et al. Induction of human tumorloaded dendritic cells. Int J Cancer 2001;91:438–47.

    CAS  PubMed  Google Scholar 

  68. Song W, Tong Y, Carpenter H, Kong HL, Crystal RG. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen. Gene Ther 2000;7:2080–6.

    CAS  PubMed  Google Scholar 

  69. Bubenik J. Genetically engineered dendritic cell-based cancer vaccines-review. Int J Oncol 2001;18:475–8.

    CAS  PubMed  Google Scholar 

  70. Coppin C, Porszolt F, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer (Cochrane review). Cochrane Database Syst Rev 2000;3:CD001425.

    PubMed  Google Scholar 

  71. Krup OC, Kroll I, Bose G, Falkenberg FW. Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. J Immunother 1999;22:525–38.

    CAS  PubMed  Google Scholar 

  72. Ryan CW, Vogelzang NJ, Dumas MC, Kuzel T, Stadler WM. Granulocyte-macrophage-colony stimulating factor in combnination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials. Cancer 2000;88:1317–24.

    CAS  PubMed  Google Scholar 

  73. Westermann J, Reich G, Kopp J, Haus U, Dorken B, Pezzutto A. Granulocyte/macrophage-colonystimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study. Cancer Immunol Immunother 2001;49:613–20.

    CAS  PubMed  Google Scholar 

  74. Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone. Anticancer Res 2001;21(1B):777–9.

    CAS  PubMed  Google Scholar 

  75. Zorn U, Duensing S, Langkopf F, Anastassiou G, Kirchner H, Hadam M, et al. Active specific immunotherapy of renal cell carcinoma: cellular and humoral immune responses. Cancer Biother Radiopharm 1997;12:157–65.

    CAS  PubMed  Google Scholar 

  76. Holtl L, Reiser C, Papesh C, Ramoner R, Herold M, Klocker H, Radmayr C, Stenzl A, Bartsch G, Thurnher M. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol 1999;161:777–82.

    CAS  PubMed  Google Scholar 

  77. Heiser A, Maurice MA, Yancey DR, Coleman DM, Dahm P, Vieweg J. Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res 2001;61:3388–93.

    CAS  PubMed  Google Scholar 

  78. Hara I, Nagai H, Miyake H, Yamanaka K, Hara S, Micallef MJ, et al. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration. Cancer Gene Ther 2000;7:83–90.

    CAS  PubMed  Google Scholar 

  79. Kugler A, Seseke F, Thelen P, Kallerhoff M, Muller GA, Stuhler G, et al. Autologous and allogeneic hybrid cell vaccine in patients with metastatic renal cell carcinoma. Br J Urol 1998;82:487–93.

    CAS  PubMed  Google Scholar 

  80. Daniels GA, Galanais E. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. Curr Opin Mol Ther 2001;3:70–6.

    CAS  PubMed  Google Scholar 

  81. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999;17:2044–9.

    CAS  PubMed  Google Scholar 

  82. Barrett AJ. Conditioning regimens for allogeneic stem cell transplants. Curr Opin Hematol 2000;7:339–42.

    CAS  PubMed  Google Scholar 

  83. Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin Nth Am 2000;27:125–35.

    CAS  Google Scholar 

  84. Kurth KH, Bouffioux C, Sylvester R, van der Meijden AP, Oosterlinck W, Brausi M. Treatment of superificial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol 2000;37 Suppl 3:1–9.

    CAS  PubMed  Google Scholar 

  85. Malmstrom P. Improved patient outcomes with BCG immunotherapy vs. chemotherapy-Swedish and worldwide experience. Eur Urol 2000;37 Suppl 1:16–20.

    CAS  PubMed  Google Scholar 

  86. Sabichi AL, Lerner SP, Grossman HB, Lippman SM. Retinoids in the chemoprevention of bladder cancer. Curr Opin Oncol 1998;10:479–84.

    CAS  PubMed  Google Scholar 

  87. Clifford JL, Sabichi AL, Zou C, Yang X, Steele VE, Kelloff GJ, et al. Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer. Cancer Epidemiol Biomarkers Prev 2001;10:391–5.

    CAS  PubMed  Google Scholar 

  88. Gan YH, Mahendran R, James K, Lawrencia C, Esuvaranathan K. Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer. Clin Immunol 1999;90:230–7.

    CAS  PubMed  Google Scholar 

  89. Patard JJ, Saint F, Velotti F, Abbou CC, Chopin DK. Immune response following intravesical bacillus Calmette-Guerin instillations in superficial bladder cancer: a review. Urol Res 1998;26:155–9.

    CAS  PubMed  Google Scholar 

  90. Brandau S, Riemensberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer 2001;92(5):697–702.

    CAS  PubMed  Google Scholar 

  91. Thalmann GN, Sermier A, Rentsch C, Mohrle K, Cecchini MG, Studer UE. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin. J Urol 2000;164:2129–33.

    CAS  PubMed  Google Scholar 

  92. Zlotta AR, van Vooren JP, Denis O, Drowart A, Daffe M, Lefevre P, et al. What are the immunologically active components of bacille Calmette-Guerin in therapy of superficial bladder cancer? Int J Cancer 2000;87:844–52.

    CAS  PubMed  Google Scholar 

  93. Buu N, Sanchez F, Schurr E. The BCG host-resistance gene. Clin Infect Dis 2000;31 Suppl 3:S81–5.

    CAS  PubMed  Google Scholar 

  94. Witjes WP, Konig M, Boeminghaus FP, Hall RR, Schulman CC, Zurlo M, et al. Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naïve patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur Urol 1999;36:576–81.

    CAS  PubMed  Google Scholar 

  95. Fleckenstein G, Osmers R, Puchta J. Monoclonal antibodies in solid tumors: approaches to therapy with emphasis on gynaecological cancer. Med Oncol 1998;15:212–21.

    CAS  PubMed  Google Scholar 

  96. Baum RP, Niesen A, Hertel A, Nancy A, Hess H, Donnerstag B, et al. Activating anti-idiotypic human anti-mouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73(3 Suppl):1121–5.

    CAS  PubMed  Google Scholar 

  97. Klimp AH, DeVries EG, Scherphof GL, Daemen T. Chemo-immunotherapy of ovarian cancer in a murine tumor model. Anticancer Res 2000;20:2585–92.

    CAS  PubMed  Google Scholar 

  98. Freedman RS, Kudelkla AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, et al Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res 2000;6:2268–78.

    CAS  PubMed  Google Scholar 

  99. Santin AD, Hermonat PL, Ravaggi A, Bellone S, Pecorelli S, Cannon MJ, et al. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 aytotoxic lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer. Am J Obstet Gynecol 2000;183:601–9.

    CAS  PubMed  Google Scholar 

  100. Gong J, Nikrui N, Chen D, Koido S, Wu Z, Tanaka Y, et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J Immunol 2000;165:1705–11.

    CAS  PubMed  Google Scholar 

  101. Parker LL, Do MT, Westwood JA, Wunderlich JR, Dudley ME, Rosenberg SA, et al. Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000;11:2377–8.

    CAS  PubMed  Google Scholar 

  102. Epenetos AA, Hird V, Lambert H, Mason P, Coulter C. Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. Int J Gynecol Cancer 2000;10(S1):44–6.

    PubMed  Google Scholar 

  103. Syrigos KN, Epenetos AA. Radioimmunotherapy of ovarian cancer. Hybridoma 1995;14:121–4.

    CAS  PubMed  Google Scholar 

  104. Dillman RO. Perceptions of Herceptin: a monoclonal antibody for the treatment of breast cancer. Cancer Biother Radiopharm 1999;1:5–10.

    Google Scholar 

  105. Stebbing J, Copson E, O’Reilly S. Herceptin (tastuzamab) in advanced breast cancer. Cancer Treat Rev 2000;26:287–90.

    CAS  PubMed  Google Scholar 

  106. Disi ML, Schiffman K, Gooley TA, McNeel DG, Rinn K, Knutson KL. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 2000;6:1347–50.

    Google Scholar 

  107. Cefai D, Morrison BW, Sckell A, Favre L, Balli M, Leunig M, Gimmi CD. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer. Int J Cancer 1999;83:393–400.

    CAS  PubMed  Google Scholar 

  108. Reilly RT, Machiels JP, Emens LA, Ercolini AM, Okoye FI, Lei RY, et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001;61:880–3.

    CAS  PubMed  Google Scholar 

  109. Kurebayashi JJ. Biological and clinical significance of her2 overexpression in breast cancer. Breast Cancer 2001;8:45–51.

    CAS  PubMed  Google Scholar 

  110. Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC-1. Vaccine 2000;18:2059–71.

    CAS  PubMed  Google Scholar 

  111. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, Snijdewint FG, Kok A, Van Kamp GJ, et al. Survival in early breast cancer patients is favourably influenced by a natural humoral immune response tp polymorphic epithelial mucin. J Clin Oncol 2000;18:574–83.

    Google Scholar 

  112. Winthrop MD, DeNardo SJ, DeNardo GL. Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer. Clin Cancer Res 1999;5(10 Suppl):3088s–3094s.

    CAS  PubMed  Google Scholar 

  113. Avigan D, Wu Z, Joyce R, Elias A, Richardson P, McDermott D, et al. Immune reconstitution following high-dose chemotherapy with stem cell rescue in patients with advanced breast cancer. Bone Marrow Transpl 2000;26:169–76.

    CAS  Google Scholar 

  114. Veronesi U, Galimberti V, Zurrida S, Pigatto F, Veronesi P, Robertson C, Paganelli G, Sciascia V, Viale G. Sentinel lymph node biopsy as an indicator for axillary dissection in early breast cancer. Eur J Cancer 2001;37:454–8.

    CAS  PubMed  Google Scholar 

  115. Lucci A Jr, Kelemen PR, Miller C 3rd, Chardkoff L, Wilson L. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coli Surg 2001;192:453–8.

    Google Scholar 

  116. Britton KE, Jan H, al-Yasi AR, Biassoni L, Carroll MJ, Granowska M. Efficacy of immunoscintigraphy for detection of lymph node metastases. Recent Results Cancer Res 2000;157:3–11.

    CAS  PubMed  Google Scholar 

  117. Kuehn T, Klauss W, Darsow M, Regele S, Flock F, Maiterth C, et al. Long-term morbidity following axillary dissection in breast cancer patients-clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000;64:275–86.

    CAS  PubMed  Google Scholar 

  118. Saida T. Recent advances in melanoma research. J Dermatol Sci 2001;26:1–13.

    CAS  PubMed  Google Scholar 

  119. Jager D, Jager E, Knuth A. Vaccinatiuon for malignant melanoma: recent developments. Oncology 2001;60:1–7.

    CAS  PubMed  Google Scholar 

  120. Kawakami Y, Suzuki Y, Shofuda T, Kiniwa Y, Inozume T, Dan K, et al. T cell immune responses against melanoma and melanocytes in cancer and autoimmunity. Pigment Cell Res 2000;13 Suppl 8:S163–9.

    Google Scholar 

  121. Waanders GA, Rimoldi D, Lienard D, Carrel S, Lejeune F, Dietrich PY, et al. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line. Clin Cancer Res 1997;3:685–96.

    CAS  PubMed  Google Scholar 

  122. Larsson M, Jin X, Ramratnam B, Ogg GS, Engelmayer J, Demoitie MA, et al. A recombinant vaccinia virus-based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS 1999;13:767–77.

    CAS  PubMed  Google Scholar 

  123. Schefford A, Assenmacher M, Reiners-Schramm L, Lauster R, Radbruch A. High-sensitivity immunofluorescence for detection of the pro-and anti-inflammatory cytokines γ-interferon and interleukin-10 on the surface of cytokine-secreting cells. Nat Med 2000;6:107–110.

    Google Scholar 

  124. Clay TM, Hobeika AC, Mosca PJ, Lyerly HK, Morse MA. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001;7:1127–35.

    CAS  PubMed  Google Scholar 

  125. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Pipekorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000;192:1637–44.

    CAS  PubMed Central  PubMed  Google Scholar 

  126. Osanto S, Schiphorst PP, Weijl NI, Dijkstra N, Van Wees A, Brouwenstein N, et al. Vaccination of melanoma patients with an allogeneic, genetically-modified interleukin 2-producing melanoma cell line. Hum Gene Ther 2000;11:739–50.

    CAS  PubMed  Google Scholar 

  127. Moller P, Moller H, Sun Y, Dorbic T, Henz BM, Wittig B, et al. Increased non-major histocompatibility complex-restricted activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells. Cancer Gene Ther 2000;7:976–84.

    CAS  PubMed  Google Scholar 

  128. Nawrocki S, Murawa P, Malicki J, Kapcinska M, Gryska K, Izycki D, et al. Genetically modified tumor vaccines (GMTV) in melanoma clinical trials. Immunol Lett 2000;74:81–6.

    CAS  PubMed  Google Scholar 

  129. Perricone MA, Claussen KA, Smith KA, Kaplan JM, Piraino S, Shankara S, et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther 2000;1:275–84.

    CAS  PubMed  Google Scholar 

  130. Abken H, Hombach A, Heuser C, Reinhold U. A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity. Rec Results Cancer Res 2001;158:249–64.

    CAS  Google Scholar 

  131. Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, et al. Generation of T-cell immunity to a murine melanoma using MART-I-engineered dendritic cells. J Immunother 2000;23:59–66.

    CAS  PubMed  Google Scholar 

  132. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E, et al. Phase I trial of intravenous peptidepulsed dendritic cells in patients with metastatic melanoma. J Immunother 2001;24:66–78.

    CAS  PubMed  Google Scholar 

  133. Hadzantonis M, O’Neill H. Review: dendritic cell immunotherapy for melanoma. Cancer Biother Radiopharm 1999;1:11–22.

    Google Scholar 

  134. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, et al. Crosspriming of naïve CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000;192:1535–44.

    CAS  PubMed Central  PubMed  Google Scholar 

  135. Waldrop SL, Davis KA, Maino VC, Picker LJ. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol 1998;161:5284–95.

    CAS  PubMed  Google Scholar 

  136. Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. Annu Rev Immunol 1999;17:781–828.

    CAS  PubMed  Google Scholar 

  137. Saikumar P, Dong Z, Mikhailov V, Denton M, Weinberg JM, Venkatachalam MA. Apoptosis: definition, mechanisms and relevance to disease. Am J Med 1999;107:489–506.

    CAS  PubMed  Google Scholar 

  138. Utz PJ, Andeson P. Life and death decisions: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Differ 2000;7:589–602.

    CAS  PubMed  Google Scholar 

  139. Konopleva M, Zhao S, Xie Z, Segall H, Younes A, Claxton DF, et al. Apoptosis. Molecules and mechanisms. Adv Exp Med Biol 1999;457:217–36.

    CAS  PubMed  Google Scholar 

  140. Nguyen T, Thomas W, Zhang XD, Gray C, Hersey P. Immunologically-mediated tumor cell apoptosis: the role of TRAIL in T cell and cytokine-mediated responses to melanoma. Forum (Genova) 2000;10:243–52.

    CAS  Google Scholar 

Download references

Authors
  1. Andrew P. Zbar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Kaplan Medical Center, PO Box 23273, King George PO Branch, 61231, Tel Aviv, Israel

    Andrew P. Zbar (Head of Colorectal Surgery,Senior Consultant Colorectal Surgeon) (Head of Colorectal Surgery,Senior Consultant Colorectal Surgeon)

  2. St James’s University Hospital, School of Medicine, Division of Surgery, University of Leeds, Clinical Sciences Building, Leeds, LS9 7TF, UK

    Pierre J. Guillou

  3. Department of Surgery, University of Alabama School of Medicine, Boshell Diabetes Building,1808 7th Avenue South, Birmingham, AL, 35233, USA

    Kirby I. Bland (Professor and Chairman Dept of Surgery) (Professor and Chairman Dept of Surgery)

  4. Oncology Unit 3rd Department Medicine, Athens Medical School Sotiria General Hospital, Athens, Greece

    Konstantinos N. Syrigos (Associate Professor of Medical Oncology, Head) (Associate Professor of Medical Oncology, Head)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag London

About this chapter

Cite this chapter

Zbar, A.P. (2002). Commentary on Section III. In: Zbar, A.P., Guillou, P.J., Bland, K.I., Syrigos, K.N. (eds) Immunology for Surgeons. Springer, London. https://doi.org/10.1007/978-1-4471-0201-4_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-0201-4_22

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-482-6

  • Online ISBN: 978-1-4471-0201-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation